724 related articles for article (PubMed ID: 8630906)
21. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
[TBL] [Abstract][Full Text] [Related]
22. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.
Pavletic Z; Benyunes MC; Thompson JA; Lindgren CG; Massumoto C; Alderson MR; Buckner CD; Fefer A
Exp Hematol; 1993 Sep; 21(10):1371-8. PubMed ID: 8359237
[TBL] [Abstract][Full Text] [Related]
23. Induction of human monocyte susceptibility to lymphokine-activated killer cell lysis by granulocyte-macrophage colony-stimulating factor.
Blanchard DK; Serbousek D; Djeu JY
Cancer Res; 1989 Sep; 49(18):5037-43. PubMed ID: 2670200
[TBL] [Abstract][Full Text] [Related]
24. Effects of lethal irradiation and cyclosporin A treatment on the growth and tumoricidal activity of a T cell clone potentially useful in cancer therapy.
Cesano A; Visonneau S; Cioé L; Clark SC; Santoli D
Cancer Immunol Immunother; 1995 Mar; 40(3):139-51. PubMed ID: 7728772
[TBL] [Abstract][Full Text] [Related]
25. Development of four donor-specific phenotypes in human long-term lymphokine-activated killer cell cultures.
Vollenweider I; Moser R; Groscurth P
Cancer Immunol Immunother; 1994 Nov; 39(5):305-12. PubMed ID: 7987862
[TBL] [Abstract][Full Text] [Related]
26. Augmentative effect of Nocardia rubra cell-wall skeleton on the induction of human lymphokine-activated killer (LAK) cells by the production of LAK cell helper factor(s).
Shirasaka T; Kawase I; Okada M; Kitahara M; Ikeda T; Komuta K; Hosoe S; Yokota S; Masuno T; Kishimoto S
Cancer Immunol Immunother; 1989; 30(4):195-204. PubMed ID: 2598189
[TBL] [Abstract][Full Text] [Related]
27. Susceptibility of monocytes to lymphokine-activated killer cell lysis: effect of granulocyte-macrophage colony-stimulating factor and interleukin-3.
Djeu JY; Widen R; Blanchard DK
Blood; 1989 Apr; 73(5):1264-71. PubMed ID: 2649172
[TBL] [Abstract][Full Text] [Related]
28. The effects of granulocyte-macrophage colony-stimulating factor on tumour-infiltrating lymphocytes from renal cell carcinoma.
Steger GG; Kaboo R; deKernion JB; Figlin R; Belldegrun A
Br J Cancer; 1995 Jul; 72(1):101-7. PubMed ID: 7599037
[TBL] [Abstract][Full Text] [Related]
29. GM-CSF-mediated proliferation induction improves the susceptibility of leukemia cells to lymphokine-activated killer cells.
Teichmann JV; Ludwig WD; Thiel E
Int J Hematol; 1992 Jun; 55(3):255-64. PubMed ID: 1498316
[TBL] [Abstract][Full Text] [Related]
30. Cytotoxicity of white blood cells activated by granulocyte-colony-stimulating factor, granulocyte/macrophage-colony-stimulating factor and macrophage-colony-stimulating factor against tumor cells in the presence of various monoclonal antibodies.
Ragnhammar P; Frödin JE; Trotta PP; Mellstedt H
Cancer Immunol Immunother; 1994 Oct; 39(4):254-62. PubMed ID: 7525059
[TBL] [Abstract][Full Text] [Related]
31. Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood.
Alderson MR; Sassenfeld HM; Widmer MB
J Exp Med; 1990 Aug; 172(2):577-87. PubMed ID: 2142722
[TBL] [Abstract][Full Text] [Related]
32. Production of granulocyte/macrophage-colony-stimulating factor by human natural killer cells. Modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor.
Levitt LJ; Nagler A; Lee F; Abrams J; Shatsky M; Thompson D
J Clin Invest; 1991 Jul; 88(1):67-75. PubMed ID: 1676038
[TBL] [Abstract][Full Text] [Related]
33. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
34. Protein A potentiates lymphokine-activated killer cell induction in normal and melanoma patient lymphocytes.
Singh KP; Shau H; Gupta RK; Kopald K; Ray PK
Immunopharmacol Immunotoxicol; 1992; 14(1-2):73-103. PubMed ID: 1597662
[TBL] [Abstract][Full Text] [Related]
35. Cytolysis of human dendritic cells by autologous lymphokine-activated killer cells: participation of both T cells and NK cells in the killing.
Parajuli P; Nishioka Y; Nishimura N; Singh SM; Hanibuchi M; Nokihara H; Yanagawa H; Sone S
J Leukoc Biol; 1999 Jun; 65(6):764-70. PubMed ID: 10380897
[TBL] [Abstract][Full Text] [Related]
36. On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine-activated killer cell activity.
Spagnoli GC; Juretic A; Schultz-Thater E; Dellabona P; Filgueira L; Hörig H; Zuber M; Garotta G; Heberer M
Cell Immunol; 1993 Feb; 146(2):391-405. PubMed ID: 8174177
[TBL] [Abstract][Full Text] [Related]
37. Dendritic cells generated in the presence of granulocyte-macrophage colony-stimulating factor and IFN-alpha are potent inducers of HIV-specific CD8 T cells.
Carbonneil C; Aouba A; Burgard M; Cardinaud S; Rouzioux C; Langlade-Demoyen P; Weiss L
AIDS; 2003 Aug; 17(12):1731-40. PubMed ID: 12891059
[TBL] [Abstract][Full Text] [Related]
38. Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study.
Westermann J; Reich G; Kopp J; Haus U; Dörken B; Pezzutto A
Cancer Immunol Immunother; 2001 Jan; 49(11):613-20. PubMed ID: 11225992
[TBL] [Abstract][Full Text] [Related]
39. Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies.
Higuchi CM; Thompson JA; Cox T; Lindgren CG; Buckner CD; Fefer A
Cancer Res; 1989 Oct; 49(20):5509-13. PubMed ID: 2477142
[TBL] [Abstract][Full Text] [Related]
40. Reduced LAK cytotoxicity of peripheral blood mononuclear cells in patients with bladder cancer: decreased LAK cytotoxicity caused by a low incidence of CD56+ and CD57+ mononuclear blood cells.
Hermann GG; Petersen KR; Steven K; Zeuthen J
J Clin Immunol; 1990 Nov; 10(6):311-20. PubMed ID: 1707414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
